| U.S. Brand Names |
| Bactroban®; Bactroban® Nasal |
 |
| Generic Available |
|
No |
|
| Synonyms |
| Mupirocin Calcium; Pseudomonic Acid A |
|
| Pharmacological Index |
|
Antibiotic, Topical |
|
| Use |
|
Topical treatment of impetigo due to Staphylococcus aureus, beta-hemolytic Streptococcus, and S. pyogenes |
|
| Pregnancy Risk Factor |
|
B |
|
| Contraindications |
|
Known hypersensitivity to mupirocin or polyethylene glycol |
|
| Warnings/Precautions |
|
Potentially toxic amounts of polyethylene glycol contained in the vehicle may be absorbed percutaneously in patients with extensive burns or open wounds; prolonged use may result in over growth of nonsusceptible organisms; for external use only; not for treatment of pressure sores |
|
| Adverse Reactions |
|
1% to 10%: Local: Burning, stinging, tenderness, edema, pain |
|
| Drug Interactions |
|
No data reported |
|
| Stability |
|
Do not mix with Aquaphor®, coal tar solution, or salicylic acid |
|
| Mechanism of Action |
|
Binds to bacterial isoleucyl transfer-RNA synthetase resulting in the inhibition of protein and RNA synthesis |
|
| Pharmacodynamics/Kinetics |
|
Absorption: Topical: Penetrates the outer layers of the skin; systemic absorption minimal through intact skin Protein binding: 95% Metabolism: Extensively to monic acid, principally in the liver and skin Half-life: 17-36 minutes Elimination: In urine |
|
| Usual Dosage |
|
Topical: Children and Adults: Apply small amount to affected area 2-5 times/day for 5-14 days Nasal: In adults (12 years of age and older), approximately one-half of the ointment from the single-use tube should be applied into one nostril and the other half into the other nostril twice daily for 5 days |
|
| Mental Health: Effects on Mental Status |
|
None noted |
|
| Mental Health: Effects on Psychiatric Treatment |
|
None noted |
|
| Dental Health: Local Anesthetic/Vasoconstrictor Precautions |
|
No information available to require special precautions |
|
| Dental Health: Effects on Dental Treatment |
|
No effects or complications reported |
|
| Patient Information |
|
For external use only. Wash hands before and after application. Apply this film over affected areas exactly as directed. Avoid getting in eyes. Report rash; persistent burning, stinging, swelling, itching, or pain. Breast-feeding precautions: Consult prescriber if breast-feeding. |
|
| Nursing Implications |
|
Not for treatment of pressure sores in elderly patients; contains polyethylene glycol vehicle |
|
| Dosage Forms |
|
Ointment, as calcium: Topical: 2% (15 g, 30 g) |
|
| References |
|
Blumer JL, Lemon E, O'Horo J, et al, "Changing Therapy for Skin and Soft Tissue Infections in Children: Have We Come Full Circle?" Pediatr Infect Dis J, 1987, 6(1):117-22. Britton JW, Fajardo JE, and Krafte-Jacobs B, "Comparison of Mupirocin and Erythromycin in the Treatment of Impetigo," J Pediatr, 1990, 117(5):827-9. Goldfarb J, Crenshaw D, O'Horo J, et al, "Randomized Clinical Trial of Topical Mupirocin Versus Oral Erythromycin for Impetigo," Antimicrob Agents Chemother, 1988, 32(12):1780-3. |
|
|
Copyright © 2007 Drugs Area |
